



**Novo Nordisk
Foundation**

c/o Michael Makanga
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d'Or
1060 Brussels
Belgium

Letter of Endorsement

Dear Sir,

On behalf of Novo Nordisk Foundation (the "Foundation"), Tuborg Havnevej 19, 2900 Hellerup, Denmark, company registration no. 10582989, and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

Established in 1924, the Foundation is an independent Danish enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people's health and the sustainability of society and the planet. Through grants, the Foundation progresses research, innovation, and development initiatives that seek to address major societal challenges, including health.

The Foundation will become a Contributing Partner to Global Health EDCTP3 JU, providing a Financial Contribution ("FC") in the form of a grant to the Work Programme 2026 and Work Programme 2027 (together, "the Project"). The total value of the FC for the Project will be up to EUR 17.975 million, allocated as set out below.

For the Work Programme 2026, the Foundation will become a Contributing Partner for the Call Topic 2 on Prevention and Management of Lower Respiratory Tract Infections in sub-Saharan Africa. The total value of the FC for the Work Programme 2026 will be up to EUR 8.475 million.

For the Work Programme 2027, the Foundation will become a Contributing Partner for the Call Topic on Post-registration Trials on the Intersection Between Infectious Diseases and Non-communicable Diseases to Deliver

19 June 2026

Page 1/3

Novo Nordisk Foundation
Tuborg Havnevej 19
DK-2900 Hellerup
Denmark

novonordiskfonden.dk
+45 3527 6600
CVR no.: 10 58 29 89

Better Clinical Care. The FC for the Work Programme 2027 is contingent upon the final call text including the following elements:

- Proposals must address ID-NCD co-occurrence by:
 - o generating evidence on how the interaction of IDs and NCDs affects prevention and treatment strategies
 - o generating data to inform clinical guidelines and public health policies on ID-NCD co-morbidities
 - o contributing to better integration of clinical care for individuals with ID-NCD co-morbidities
- Proposals focusing exclusively on ID-ID co-infection are considered out of scope.

The total value of the FC for the Work Programme 2027 will be up to EUR 9.5 million.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe; and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the “need-to-know” principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. The Foundation and Global Health EDCTP3 JU shall enter into a grant agreement, which shall constitute the governing document with respect to the Project, setting out the specific requirements and provisions applicable to the FC, including any additional modalities regarding the provision thereof, pursuant to which the FC shall be transferred directly to Global

Health EDCTP3 JU.

6. If our letter is accepted, and without prejudice to point 2, we authorise Global Health EDCTP3 JU to communicate about our contribution and to display our logo in its public communication materials for the purpose of acknowledging our role as a contributing partner.

Hellerup, 24 June 2026



Flemming Konradsen

Chief Scientific Officer of Health
Novo Nordisk Foundation